Richard R Neubig (R R Neubig)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 19

Top Venues

International journal of cancer

Scientific reports

ACS omega

Journal of neurophysiology

Michigan State University

Harvard University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Michigan State University Jul 01 2013

United States

Professor & Chair :: Pharmacology & Toxicology

University of Michigan Medical School

United States

Asst/Assoc/Professor :: Pharmacology

University of Michigan Hospital

United States

Intern/Resident :: Internal Medicine

Education History

Harvard University

United States

PHD :: Pharmacology

University of Michigan

United States

BSC :: Chemistry

Publications

Bardees M Foda, Sean A Misek, Kathleen A Gallo, Richard R Neubig
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. International journal of cancer (2024)
Bardees M Foda, Sean A Misek, Kathleen A Gallo, Richard R Neubig
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. International journal of cancer 155 (7) (2024)
Bardees M Foda, Sean A Misek, Kathleen A Gallo, Richard R Neubig
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. International journal of cancer (2024)
Sophia D Staerz, Erika M Lisabeth, Evert Njomen, Thomas S Dexheimer, Richard R Neubig, Jetze J Tepe
Development of a Cell-Based AlphaLISA Assay for High-Throughput Screening for Small Molecule Proteasome Modulators. ACS omega 8 (17) (2023)
Bardees M Foda, Richard R Neubig
Role of Rho/MRTF in Aggressive Vemurafenib-Resistant Murine Melanomas and Immune Checkpoint Upregulation. International journal of molecular sciences 24 (18) (2023)
Sophia D Staerz, Erika M Lisabeth, Evert Njomen, Thomas S Dexheimer, Richard R Neubig, Jetze J Tepe
Development of a Cell-Based AlphaLISA Assay for High-Throughput Screening for Small Molecule Proteasome Modulators. ACS omega 8 (17) (2023)
Huijie Feng, Yukun Yuan, Michael R Williams, Alex J Roy, Jeffery R Leipprandt, Richard R Neubig
Mice with monoallelic GNAO1 loss exhibit reduced inhibitory synaptic input to cerebellar Purkinje cells. Journal of neurophysiology 127 (3) (2022)
Kathryn M Appleton, Charuta C Palsuledesai, Sean A Misek, Maja Blake, Joseph Zagorski, Kathleen A Gallo, Thomas S Dexheimer, Richard R Neubig
Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines. Cancers 13 (9) (2021)
Casandra L Larrivee, Huijie Feng, Josiah A Quinn, Vincent S Shaw, Jeffrey R Leipprandt, Elena Y Demireva, Huirong Xie, Richard R Neubig
Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone. The Journal of pharmacology and experimental therapeutics 373 (1) (2020)
Ana S Leal, Sean A Misek, Erika M Lisabeth, Richard R Neubig, Karen T Liby
The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Scientific reports 9 (1) (2019)
Vanessa Benham, Blair Bullard, Thomas S Dexheimer, Matthew P Bernard, Richard R Neubig, Karen T Liby, Jamie J Bernard
Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay. Scientific reports 9 (1) (2019)
Huijie Feng, Casandra L Larrivee, Elena Y Demireva, Huirong Xie, Jeff R Leipprandt, Richard R Neubig
Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes. PloS one 14 (1) (2019)
Erika M Lisabeth, Dylan Kahl, Indiwari Gopallawa, Sarah E Haynes, Sean A Misek, Phillip L Campbell, Thomas S Dexheimer, Dinesh Khanna, David A Fox, Xiangshu Jin, Brent R Martin, Scott D Larsen, Richard R Neubig
Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. ACS pharmacology & translational science 2 (2) (2019)
Dylan J Kahl, Kim M Hutchings, Erika Mathes Lisabeth, Andrew J Haak, Jeffrey R Leipprandt, Thomas Dexheimer, Dinesh Khanna, Pei-Suen Tsou, Phillip L Campbell, David A Fox, Bo Wen, Duxin Sun, Marc Bailie, Richard R Neubig, Scott D Larsen
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. Journal of medicinal chemistry 62 (9) (2019)
Sean A Misek, K M Appleton, T S Dexheimer, E M Lisabeth, R S Lo, S D Larsen, K A Gallo, Richard R Neubig
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells. Oncogene 39 (7) (2019)
Anne M Scott, Zhe Zhang, Liang Jia, Ke Li, Qinghua Zhang, Thomas Dexheimer, Edmund Ellsworth, Jianfeng Ren, Yu-Wen Chung-Davidson, Yao Zu, Richard R Neubig, Weiming Li
Spermine in semen of male sea lamprey acts as a sex pheromone. PLoS biology 17 (7) (2019)
Vincent S Shaw, Mohammadjavad Mohammadi, Josiah A Quinn, Harish Vashisth, Richard R Neubig
An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19. Molecular pharmacology 96 (6) (2019)
Hossein Mohammadiarani, Vincent S Shaw, Richard R Neubig, Harish Vashisth
Interpreting Hydrogen-Deuterium Exchange Events in Proteins Using Atomistic Simulations: Case Studies on Regulators of G-Protein Signaling Proteins. The journal of physical chemistry. B 122 (40) (2018)
Vincent S Shaw, Hossein Mohammadiarani, Harish Vashisth, Richard R Neubig
Differential Protein Dynamics of Regulators of G-Protein Signaling: Role in Specificity of Small-Molecule Inhibitors. Journal of the American Chemical Society 140 (9) (2018)

Richard R Neubig.css-eqlu8i{font-size:small;padding-left:4px;} (R R Neubig)

Publication Activity (10 Years)

Top Topics

Top Venues

Richard R Neubig (R R Neubig)